

# Chris Thompson on eResearch's Update Equity Research Report on EQ Inc.

In a recent InvestorIntel interview, Tracy Weslosky spoke with Chris Thompson, President of eResearch Corp. about their recent Update Equity Research Report on EQ Inc. ("EQ Works") (TSXV: EQ | OTC: CYPXF).

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Chris went on to say that EQ's proprietary SaaS platform uses location and geospatial data to enable business to close the loop between digital and real-world consumer actions through targeted advertising. Referencing how EQ is one of the largest providers of location-based data in Canada with 96% of its revenue coming from Canada, has great growth potential in the US. With EQ registering 100% data growth last year, Chris estimates overall revenue to grow "...about 40% from 2020 to 2021."

To watch the full interview, click here

## About eResearch Corporation

eResearch Corporation is a respected source for institutional-quality, equity research focused primarily on small- and mid-cap companies. The focus is on identifying companies that have interesting prospects, sound management, and significant potential for share price appreciation. The company complements its corporate research coverage with a diversified selection of informative, insightful, and thought-provoking research publications from a wide variety of investment professionals. The professional investment research and analysis is provided directly to the subscriber network of discerning investors, and electronically through its

website, [www.eresearch.com](http://www.eresearch.com)

## About EQ Works

EQ Works enables businesses to understand, predict, and influence customer behaviour. Using unique data sets, advanced analytics, machine learning and artificial intelligence, EQ Works creates actionable intelligence for businesses to attract, retain, and grow the customers that matter most. The Company's proprietary SaaS platform mines insights from movement and geospatial data, enabling businesses to close the loop between digital and real-world consumer actions.

To learn more about EQ Inc., [click here](#)

**Disclaimer:** This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial

condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [www.Sedar.com](http://www.Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).

---

## **Warrant Exercise Builds Treasury for Perimeter's 2021 Commercialization Efforts**

Last week, Perimeter Medical Imaging AI, Inc. (TSXV: PINK) announced that approximately 2.35 million warrants subject to an accelerated expiry were exercised, resulting in cash proceeds to the company of over C\$4.7 million.

Inclusive of the C\$4.7 million raised from the exercise of accelerated warrants noted above, Perimeter received over C\$7.28 million from the accelerated warrant exercise and can expect a further C\$0.68 million if the remaining warrants are exercised by March 8.

The company plans to use the proceeds in its commercialization and development plans to bring Perimeter's medical imaging solution to the market in 2021. Perimeter's direct clinical sales efforts include a limited market release of the platform this quarter with a broader commercial launch in the second quarter.

**Perimeter's OTIS™ Platform**

Perimeter is a medical technology company utilizing ultra-high-resolution, real-time, advanced imaging tools in cancer surgeries to improve patient outcomes and reduce costs in the healthcare system.

Perimeter's OTIS™ platform, cleared by the FDA as an imaging tool, is a system that provides surgeons, radiologists, and pathologists with ultra-high-resolution, sub-surface image volumes to allow clinicians to visualize microscopic tissue structures during a clinical procedure.

### **The Problem Being Solved**

According to Dr. Alastair Thompson, MD, a surgical oncologist and professor at Baylor, *"One of the big problems in breast cancer surgery is that in about one in four women on whom we do a lumpectomy to remove cancer, we fail to get clear margins."*

Therefore doctors are searching for an effective and user-friendly tool to help identify that the breast cancer has been removed from a woman's breast.

Baylor is one of many institutions that is conducting a study with Perimeter's medical imaging system for providing real-time, high-resolution images of the removed tissues to assist cancer surgeons in making better decisions during operations.

Hospitals see this type of system could lead to a large improvement in patient care and reduce the need for second surgeries.

### **Atlas AI Project – Artificial Intelligence (AI) / Machine Learning (ML) Tools**

In addition, Perimeter is advancing its advanced AI/ML image assessment tools through clinical development through its Atlas AI project.

Backed by a \$7.4 million grant awarded by the Cancer

Prevention and Research Institute of Texas (CPRIT), a leading state body that funds cancer research, the project will collect images of breast tumors from up to 400 patients for the purpose of training and testing Perimeter's "ImgAssist" AI technology to increase the efficiency of image review.

AI and analytics are seen as a way to address the inefficiencies and challenges that current operating rooms are facing in identifying cancerous tissues. According to the company, currently 1 in 4 patients who receive a lumpectomy has to come back for a second operation because the surgeon did not remove all of the cancer cells.

### **Focus on Breast Cancer but Applications Beyond**

Cancer continues to grow amongst the population and puts a burden on the healthcare system. According to the World Cancer Research Fund, breast cancer is the most common cancer in women worldwide, representing about 25 percent of all cancers in women.

In 2021, Breastcancer.org estimates that over 330,000 new cases of breast cancer are expected to be diagnosed in the United States and over 43,000 women are expected to die from breast cancer.

While currently focusing on deployments targeting breast cancer centers, OTIS™ has applications beyond breast cancer and into the larger multi-billion-dollar cancer surgery market.

### **Final Thoughts**

According to a recent industry report from Markets and Markets, the Surgical Imaging Market is projected to grow from US\$1.8 billion in 2020 and reach US\$2.4 billion by 2025, growing by 6.3% annually.





One of the major factors driving the growth of this market

includes the increasing demand for minimally invasive procedures that Perimeter's platform addresses.

With the commercial launch of the product scheduled for this year, Perimeter has the potential to benefit from this growing market.

## Perimeter's Medical Device Platform

Disruptive technology comprised of four key components

<p><b>OTIS™ Optical Tissue Imaging Console</b></p>  <p><b>Wide-Field OCT (100X coverage)</b></p>	<p><b>OTIS™ Tissue Immobilization System (single use consumable)</b></p>  <p><b>Aids in positioning diverse tissue types</b></p>	<p><b>Perimeter's Proprietary Image Library - <i>Atlas</i></b></p>  <p><b>Broad based tissue library with pathology verified tissues structure correlations</b></p>	<p><b>Perimeter's Proprietary AI - <i>ImgAssist</i></b></p>  <p><b>Provide "look here" guidance to speed up image review</b></p>
--	---	---	---

SOURCE :

---

# Thompson on DIAGNOS and the 'exploding' AI healthtech industry

*AI Healthcare Provider Diagnos Continues*

## ***to Sign Deals and Partnerships Amid COVID-19 Crisis***

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF | FSE:4D4A), a software platform provider for the early detection of critical health issues through the use of Artificial Intelligence (“AI”) and Machine Learning (“ML”), continues to sign deals and partnerships amid the current COVID-19 health crisis.

Diagnos’ CARA (“Computer Assisted Retina Analysis”) telemedicine platform, delivers eye care and disease diagnosis through standard fundus photography, which involves photographing the rear of an eye, and Diagnos’ patented image processing and AI analysis.

### **New 3-Year Agreement with University of Montreal Hospital Centre**

On January 19, Diagnos announced a three-year partnership agreement with the Center Hospitalier de l’Université de Montréal (“CHUM”) on AI projects related to the early detection of various retinal diseases.

Since 2018, Diagnos has been working with CHUM and using AI to screen for diabetic retinopathy and added a second screening site in the ophthalmology department in 2019 to help improve the screening process for patients with more serious conditions.

The new 3-year clinical trial aims to validate if the AI algorithm (“NeoRetina”) developed by Diagnos to detect the presence of diabetic retinopathy, can detect this disease and grade its severity by the analysis of fundus photographs when compared with traditional methods.

According to the clinical trial information, more than 10% of the population of Quebec (approximately 900,000 people), suffer from diabetes and around 40% of people with diabetes

suffer from diabetic retinopathy.

Retinopathy is any damage to the retina of the eyes, which may cause vision impairment, and early detection and regular check-ups are important in preventing the progression of the disease.

Dr. Fabrice Brunet, President and CEO of CHUM, commented, “We are pleased to be working with Diagnos to bring innovation and excellence in care to patients. The evaluation and refinement of Diagnos technology using artificial intelligence in the early detection of certain diseases by our ophthalmology, endocrinology, and now cardiology teams contribute to improving the quality and safety of the care provided to the population.”

### **New Clinics in Saudi Arabia and New Rollouts Planned in Second Half of 2021**

On January 14, Diagnos announced the opening of five new screening clinics at different locations of Magrabi Hospitals & Centers located in Riyadh, Saudi Arabia, with the help of its Saudi business partner, Kanhoor Medical Co.

Magrabi is a provider of Ears-Nose-and-Throat (“ENT”), Dentistry, and Ophthalmology services with more than 35 locations in the Middle East and North Africa and delivers eye care to more than 1 million patients annually.

After 2 field trials using Diagnos’ AI-assisted screening platform, Magrabi is launching the new locations to increase the availability of the CARA service to its diabetic patients and also to reduce wait times.

The plan between Diagnos, Magrabi, and Kanhoor is to rollout the CARA platform to the remaining 22 Magrabi hospitals in Saudi Arabia in the second half of 2021 and then extend the service to the other Magrabi hospitals in the Middle East and Africa.



## **Healthcare Diagnosis Market Exploding**

According to a 2020 industry report on the Healthcare Diagnosis market, AI in the healthcare diagnosis market was valued at US\$3.6 billion in 2019 and is forecasted to reach US\$66.8 billion by 2027, growing by a staggering 44% annually.

One of the largest growth segments is AI-assisted diagnostic solutions in areas such as cancer detection, cardiovascular disease, eye care, and radiology.

## **Worldwide Commercialization**

Diagnos currently operates screening sites in 15 countries with certifications from regulatory bodies in various countries including the U.S., Canada, the European Union, and Mexico. In 2020, Diagnos signed partnerships and commercial agreements with companies that serve patients in Canada, Colombia, Guatemala, Mexico, and southern California.

## **Final Comments**

In a recent interview, Andre Larente, CEO of Diagnos, commented that the company is fully funded for the next 18 months and he expects that more existing clients are going to restart their operations soon, which should increase revenue for Diagnos.

In addition, he said the company has a “strong pipeline” that could result in new deal announcements during the year.

Finally, screening for diabetic retinopathy is just one application of Diagnos’ AI technology and the company expects to make announcements with new partners to use the technology to detect other health issues, such as cardiovascular problems, including hypertension.

Meanwhile, even after Diagnos’ recent stock increase, the company’s market capitalization is less than C\$43 million. With its recent announcements and rollout trajectory, the low

valuation makes it a prime takeover target for any consolidator executing a roll-up strategy in the AI healthtech industry.

---

# **Drolet Stock Notes on Predictiv AI: Helping businesses and organizations make smarter decisions using advanced artificial intelligence and deep machine learning**

Mario Drolet, President of MI3 Communications Financières Inc. (MI3), released his Drolet Stock Notes on Predictiv AI Inc. (TSXV: PAI) on December 7, 2020 for exclusive distribution on InvestorIntel. Highlights include:

- Predictiv AI's proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector. Our wholly-owned subsidiaries include AI Labs Inc. and Weather Telematics Inc.
- AI Labs designed, engineered and developed ThermalPass™, a fever detection system approved by Health Canada, to mitigate the spread of contagions in public places, helping companies and employers fight against COVID-19.
- PAI rebounding ... MI3 next short-term target: \$0.30
- Support: S2; \$0.16 S1; \$0.20 Resistance: R1; \$0.22

R2; \$0.30



## About Predictiv AI:

Predictiv AI Inc. [www.predictiv.ai](http://www.predictiv.ai) is a technology company which helps businesses and organizations make smarter decisions using advanced artificial intelligence, deep machine learning and data science techniques. Its Weather Telematics Inc. subsidiary uses patented air quality monitoring sensors to provide predictive weather risk information to the insurance, logistics, fleet management and public safety sectors. The Company's R&D division, AI Labs Inc., develops new products that solve real-world business problems. The joint venture with Commersive Solutions Corp. is developing innovative technologies for use in various public spaces, starting with the ThermalPass™ fever detection system.

**PLEASE DO YOUR DUE DILIGENCE**

*Disclaimer: This Mario Drolet Stock Notes are produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI<sup>3</sup>, emanating from sources deemed to be reliable. MI<sup>3</sup> Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI<sup>3</sup> Communications Financières are prohibited from trading the securities of the company and MI<sup>3</sup> Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.*

---

## **Diagnos' AI Platform to Fight Vision Loss Continues to Expand Globally**

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a software platform provider for the early detection of critical health issues through the use of Artificial Intelligence ("AI") and Machine Learning ("ML"), and it **continues to expand globally with recent deals and government financing support.**

Utilizing AI and ML, Diagnos developed a Computer Assisted Retina Analysis ("CARA") software platform to process image data, making standard retinal images sharper, clearer, and easier to read. This technology assists healthcare specialists in the detection of vision loss, including diabetic

retinopathy.

CARA is a teleophthalmology platform, a branch of telemedicine, which delivers eye care through digital medical equipment and telecommunications technology. The CARA platform integrates with various types of existing retinal cameras at the point of care, is compatible with all recognized image formats, and is Electronic Medical Records (“EMR”) compatible.

### **Digital Health Surging**

AI technology is spreading rapidly into various verticals including automotive, healthcare, and pharmaceuticals. According to ABI Research, global AI venture capital investments in the healthcare and pharmaceutical sectors reached \$2.4 billion in 2019, up 140%, compared with \$1 billion in the prior year.

In the healthcare industry, companies are leveraging AI to overcome human’s lack of ability to detect pertinent details in data from various sources, including photos, microscopic images, X-rays, CT scans, and MRI scans.

During the current COVID-19 health crisis, with shelter-at-home orders, telemedicine and remote monitoring tools have seen a growth in demand as hospitals focus on keeping patients safe while delivering care.

### **Diagnos Client Signings Continue**

Recent client successes have included:

- Last month, Diagnos announced a contract with Devlyn Grupo, an optical retailer with over 900 stores in Mexico and Guatemala. Devlyn will test the CARA platform for diabetic retinopathy screening at select locations with a planned larger roll out to more stores in early 2021.
- In September, Diagnos reported that it re-signed a U.S.-

based client, Chaparral Medical Group, to another three-year agreement. Chaparral is a 60 physician multi-specialty group serving 23 clinics in Southern California.

- In July, Diagnos signed a service agreement with the Colombian Telemedicine Centre Ltd (“CTMC”) in Colombia, South America. The CTMC selected the CARA platform to start screening Colombia’s population in conjunction with largest vision specialist center in the country.
- In June, Diagnos executed an agreement with Labtician Ophthalmics, a Toronto-based surgical eye care products and equipment company with customers across Canada, and Labtician will use Diagnos’AI solution to monitor ocular health in its diabetic patients.

### **Well Funded for Growth**

Diagnos is well funded after raising \$2.1M in capital earlier this year and then receiving a \$2M, 10-year, interest-free loan from the government of Quebec via the Economic Development Fund to support the commercialization of the CARA platform globally.

The CARA platform is securely accessible over the Internet and Diagnos currently operates screening sites in 15 countries with certifications from regulatory bodies in various countries including the U.S., Canada, the European Union, and Mexico.

Meanwhile, even after Diagnos’ recent stock jump, the Company’s market capitalization is only \$32.5M and makes it a prime takeover target for any consolidator executing a roll-up strategy in the healthtech industry.

---

# MI3 Market Alert: Bringing Artificial Intelligence trading platform to the 5.0 level

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on QuantGate Systems Inc. (OTC: PRFC) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on QuantGate Systems Inc.

- QuantGate Systems, Inc. is a diversified fintech company which continues to expand its suite of advanced proprietary solutions like Artificial Intelligence.
- The company has developed the Pilot Trading AI retail and the Hydra robotic institutional trading platforms.
- QuantGate systems recently appointed Wall Street professional Leonardo Cardoso, CFA to lead worldwide development efforts
- The company expanded distribution of Pilot Trading with TradeStation Securities
- PRFC shares surged in Volume and price last week over 20.5 Million shares traded over the last three sessions. (first sign of material market activity over the last two years)
- Support: S2; \$0.0050 – S1; \$0.015      Resistance: R1; \$0.0275 – R2; \$0.04



## About QuantGate Systems Inc.

QuantGate Systems has developed the world's first real-time market sentiment and perception analysis system for financial markets utilizing cutting edge AI and machine learning proprietary technologies.

### PLEASE DO YOUR DUE DILIGENCE

*Disclaimer: This MI3 Technical Note produced by MI<sup>3</sup> Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI<sup>3</sup> Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are*



*prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.*

---

## **2018 was a big year for tech, so what's in store for 2019?**

Technology innovation is moving so fast you can be forgiven for thinking it's moving too fast. What was predicted one year ago to be the next big thing may have already been replaced with the latest and greatest concept.

2018 was a big year for innovation in technology with that trend expected to continue in 2019. For entrepreneurs this presents a challenge as not all new technology ends up catching on, so it's important to be careful with R&D dollars and investments. Remember technology is a tool to enable business to run more efficiently and more economically.

### **Big technology trends in 2019**

Three big trends for 2019 evolve around 5G, the Internet of Things (IoTs), and Artificial Intelligence (AI). Many other new technology trends will be enabled under these umbrellas accelerating research and development (R&D) in blockchain, mobile app development, autonomous vehicles, data analytics, smart cities and buildings, and ideas yet to be thought of.

5G is the next generation of radio access (wireless) networks delivering predicted speeds of up to 100 times faster than 4G. 5G is starting to be rolled out now in selected capital cities around the globe. Many new smartphones in 2019 will offer 5G connectivity and hence incredible online performance.

The Internet of Things will involve all things being connected online, and will be supported by 5G networks. For example a motion sensor in your home will inform your smartphone of a possible intruder, or you can remotely turn on your washing machine from work.



Artificial Intelligence is a general term for machine learning. We already see this with online “bots”, some personal robots or assistants (Amazon “Echo” etc), and with the way big companies such as Facebook use their “like” system for targeted advertising. Of course this is just the very beginning of AI, and it will perhaps be the biggest technology trend of the next decade.

Blockchain is a secure decentralized digital ledger that can't be altered. It's possible that in the future every recorded piece of digital data can be stored this way. It can mean all transactions an individual or a company makes can be recorded. Looking ahead it is quite likely we will follow China's lead and use our smartphone to simply purchase all our goods wherever we go. A cashless society recorded on the blockchain.

## **A brief look at a few of the innovative technology related companies we follow at Investorintel**

**Cobalt Blockchain Inc.** (TSXV: COBC) is working with partners to develop a blockchain-based reporting platform to provide greater certainty of provenance and further assurance that all minerals (notably cobalt) procured are ethically sourced.

**Global Blockchain Technologies** (CSE:BL0C) “BL0C” is an investment company that provides investors access to a mixture of assets in the blockchain space, strategically chosen to balance stability and growth. BL0C invests in new markets enabled by blockchain technology. On December 17, 2018, BL0C made a key acquisition by acquiring 100% of the issued and outstanding shares of X2 Games. BL0C and X2 Games have initiated a comprehensive strategy to optimize BL0C’s assets towards gaming, eSports, and AI. BL0C’s assets will be leveraged to support X2’s pursuit of disruptive gaming interfaces.

**Global Cannabis Applications Corp.** (CSE: APP | OTCQB: FUAPF) designs, develops, markets, and acquires data technologies for the cannabis industry by applying artificial intelligence, blockchain, and crypto-currency to improve cannabis health sciences. The Company mission is to build a technology-enabled community to improve health and wellness.



**Internet of Things Inc.** (TSXV: ITT) operate as an Internet of Things technology accelerator and industry investment acquisition company. In other words they buy up early stage promising IoTs companies.

**NanoSphere Health Sciences Inc.** (CSE: NSHS) do not technically fit into this category but they are doing some good things with bio tech. One of their great products is the only patented nano-particle delivery system to transport the highest level of therapeutic agents directly to the bloodstream, therefore removing the need for needles.

**Siyata Mobile Inc.** (TSXV: SIM | OTCQX: SYATF) provide an all in one 4G device that reduces clutter on company fleet dashboards. The tablet style device runs mobile apps that eliminate the use for a cell phone, a 2 way radio communications device, or even a GPS navigation system. Siyata plan to be first to market with a 5G dedicated in-vehicle device.

By no means is this a complete list but rather a brief look at some key 2019 technology trends, many of which will be showcased at the upcoming Cantech Investment Conference in Toronto Canada, January 29-30, 2019. InvestorIntel will be attending as a media partner, so we hope to see you there.